Los puntos clave no están disponibles para este artículo en este momento.
DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK ClinicalTrials.gov number, NCT00604214.).
Ranieri et al. (Thu,) studied this question.